Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra

T. Diab, Matthew Allen, David Burr

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Summary: We aimed to determine whether trabecular bone in sites that have different surface-based remodeling rates, the femoral neck and vertebra, are differently affected by alendronate treatment. Alendronate treatment resulted in similar levels of turnover in both sites, suggesting that a lower limit of bone turnover suppression with alendronate may exist. Introduction: Bone turnover suppression in sites that already have a low surface-based remodeling rate may lead to oversuppression that could have negative effects on the biomechanical properties of bone. The goal was to determine how alendronate suppresses bone turnover at sites with different surface-based remodeling rates. Methods: Dynamic histomorphometric parameters were assessed in trabecular bone of the femoral neck and lumbar vertebrae obtained from skeletally mature beagles treated with saline (1 ml/kg/day) or alendronate (ALN 0.2 or 1.0 mg/kg/day). The ALN0.2 and ALN1.0 doses approximate, on a milligram per kilogram basis, the clinical doses used for the treatment of postmenopausal osteoporosis and Paget's disease, respectively. Results: Alendronate treatment resulted in similar absolute levels of bone turnover in the femoral neck and vertebrae, although the femoral neck had 33% lower pre-treatment surface-based remodeling rate than the vertebra (p∈<∈0.05). Additionally, the high dose of alendronate (ALN 1.0) suppressed bone turnover to similar absolute levels as the low dose of alendronate (ALN 0.2) in both sites. Conclusions: Alendronate treatment may result in a lower limit of trabecular bone turnover suppression, suggesting that sites of low pre-treatment remodeling rate are not more susceptible to oversuppression than those of high pre-treatment remodeling rate.

Original languageEnglish
Pages (from-to)647-652
Number of pages6
JournalOsteoporosis International
Volume20
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Alendronate
Bone Remodeling
Femur Neck
Spine
Cancellous Bone
Lumbar Vertebrae
Postmenopausal Osteoporosis
Bone and Bones

Keywords

  • Animal models
  • Anti-remodeling
  • Bisphosphonates
  • Histomorphometry

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra. / Diab, T.; Allen, Matthew; Burr, David.

In: Osteoporosis International, Vol. 20, No. 4, 04.2009, p. 647-652.

Research output: Contribution to journalArticle

@article{39599bf1746e4f2f8b40fa7be7f4c520,
title = "Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra",
abstract = "Summary: We aimed to determine whether trabecular bone in sites that have different surface-based remodeling rates, the femoral neck and vertebra, are differently affected by alendronate treatment. Alendronate treatment resulted in similar levels of turnover in both sites, suggesting that a lower limit of bone turnover suppression with alendronate may exist. Introduction: Bone turnover suppression in sites that already have a low surface-based remodeling rate may lead to oversuppression that could have negative effects on the biomechanical properties of bone. The goal was to determine how alendronate suppresses bone turnover at sites with different surface-based remodeling rates. Methods: Dynamic histomorphometric parameters were assessed in trabecular bone of the femoral neck and lumbar vertebrae obtained from skeletally mature beagles treated with saline (1 ml/kg/day) or alendronate (ALN 0.2 or 1.0 mg/kg/day). The ALN0.2 and ALN1.0 doses approximate, on a milligram per kilogram basis, the clinical doses used for the treatment of postmenopausal osteoporosis and Paget's disease, respectively. Results: Alendronate treatment resulted in similar absolute levels of bone turnover in the femoral neck and vertebrae, although the femoral neck had 33{\%} lower pre-treatment surface-based remodeling rate than the vertebra (p∈<∈0.05). Additionally, the high dose of alendronate (ALN 1.0) suppressed bone turnover to similar absolute levels as the low dose of alendronate (ALN 0.2) in both sites. Conclusions: Alendronate treatment may result in a lower limit of trabecular bone turnover suppression, suggesting that sites of low pre-treatment remodeling rate are not more susceptible to oversuppression than those of high pre-treatment remodeling rate.",
keywords = "Animal models, Anti-remodeling, Bisphosphonates, Histomorphometry",
author = "T. Diab and Matthew Allen and David Burr",
year = "2009",
month = "4",
doi = "10.1007/s00198-008-0717-9",
language = "English",
volume = "20",
pages = "647--652",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "4",

}

TY - JOUR

T1 - Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra

AU - Diab, T.

AU - Allen, Matthew

AU - Burr, David

PY - 2009/4

Y1 - 2009/4

N2 - Summary: We aimed to determine whether trabecular bone in sites that have different surface-based remodeling rates, the femoral neck and vertebra, are differently affected by alendronate treatment. Alendronate treatment resulted in similar levels of turnover in both sites, suggesting that a lower limit of bone turnover suppression with alendronate may exist. Introduction: Bone turnover suppression in sites that already have a low surface-based remodeling rate may lead to oversuppression that could have negative effects on the biomechanical properties of bone. The goal was to determine how alendronate suppresses bone turnover at sites with different surface-based remodeling rates. Methods: Dynamic histomorphometric parameters were assessed in trabecular bone of the femoral neck and lumbar vertebrae obtained from skeletally mature beagles treated with saline (1 ml/kg/day) or alendronate (ALN 0.2 or 1.0 mg/kg/day). The ALN0.2 and ALN1.0 doses approximate, on a milligram per kilogram basis, the clinical doses used for the treatment of postmenopausal osteoporosis and Paget's disease, respectively. Results: Alendronate treatment resulted in similar absolute levels of bone turnover in the femoral neck and vertebrae, although the femoral neck had 33% lower pre-treatment surface-based remodeling rate than the vertebra (p∈<∈0.05). Additionally, the high dose of alendronate (ALN 1.0) suppressed bone turnover to similar absolute levels as the low dose of alendronate (ALN 0.2) in both sites. Conclusions: Alendronate treatment may result in a lower limit of trabecular bone turnover suppression, suggesting that sites of low pre-treatment remodeling rate are not more susceptible to oversuppression than those of high pre-treatment remodeling rate.

AB - Summary: We aimed to determine whether trabecular bone in sites that have different surface-based remodeling rates, the femoral neck and vertebra, are differently affected by alendronate treatment. Alendronate treatment resulted in similar levels of turnover in both sites, suggesting that a lower limit of bone turnover suppression with alendronate may exist. Introduction: Bone turnover suppression in sites that already have a low surface-based remodeling rate may lead to oversuppression that could have negative effects on the biomechanical properties of bone. The goal was to determine how alendronate suppresses bone turnover at sites with different surface-based remodeling rates. Methods: Dynamic histomorphometric parameters were assessed in trabecular bone of the femoral neck and lumbar vertebrae obtained from skeletally mature beagles treated with saline (1 ml/kg/day) or alendronate (ALN 0.2 or 1.0 mg/kg/day). The ALN0.2 and ALN1.0 doses approximate, on a milligram per kilogram basis, the clinical doses used for the treatment of postmenopausal osteoporosis and Paget's disease, respectively. Results: Alendronate treatment resulted in similar absolute levels of bone turnover in the femoral neck and vertebrae, although the femoral neck had 33% lower pre-treatment surface-based remodeling rate than the vertebra (p∈<∈0.05). Additionally, the high dose of alendronate (ALN 1.0) suppressed bone turnover to similar absolute levels as the low dose of alendronate (ALN 0.2) in both sites. Conclusions: Alendronate treatment may result in a lower limit of trabecular bone turnover suppression, suggesting that sites of low pre-treatment remodeling rate are not more susceptible to oversuppression than those of high pre-treatment remodeling rate.

KW - Animal models

KW - Anti-remodeling

KW - Bisphosphonates

KW - Histomorphometry

UR - http://www.scopus.com/inward/record.url?scp=62149101092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62149101092&partnerID=8YFLogxK

U2 - 10.1007/s00198-008-0717-9

DO - 10.1007/s00198-008-0717-9

M3 - Article

C2 - 18716822

AN - SCOPUS:62149101092

VL - 20

SP - 647

EP - 652

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 4

ER -